Pope Janet E, Krizova Adriana, Ouimet Janine M, Goodwin Jodi L, Lankin Matthew
Division of Rheumatology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada.
J Rheumatol. 2004 Feb;31(2):274-9.
To investigate the prevalence of infections, particularly the frequency of shingles and the timing of varicella zoster virus (VZV) reactivation, and antibiotic use, vaccinations, and joint trauma prior to and at diagnosis of systemic lupus erythematosus (SLE).
We sent questionnaires to patients with SLE (n = 93) and controls with noninflammatory musculoskeletal disorders (MSK; n = 353) including osteoarthritis, fibromyalgia, and tendonitis. We matched SLE patients to controls for sex (up to 1:3).
The response rate in SLE was 66% and in controls 69% (p < 0.53). Four of 61 SLE patients and 12 of 173 controls were men. The mean disease duration in the SLE group was 8 +/- 1 years compared to 10 +/- 1 years in controls (p < 0.23). SLE patients were significantly younger than controls (mean age of SLE patients 49 +/- 2 vs 57 +/- 1 years for controls; p < 0.0004), and results were adjusted for age. A significantly higher proportion of SLE participants had a history of VZV (shingles) (19% vs 7%, respectively; OR 2.98, p < 0.003), whereas rubella was reported less in SLE (23% vs 42%; OR 0.43, p < 0.03). VZV infections were clustered just prior to or after diagnosis in SLE but were more widely spaced temporally in the controls (1 +/- 4.5 years after the diagnosis of SLE vs -14.7 +/- 4 years before the diagnosis of noninflammatory MSK disorder; p < 0.003). Diagnosis of shingles was observed in 6 of 11 SLE patients within +/- 2 years of SLE diagnosis, whereas only 2 of 15 controls had shingles within +/- 2 years of diagnosis (OR 7.2, p < 0.03). Only 2 patients with SLE were taking immunosuppressive drugs or steroids at time of shingles, so immunosuppressive therapy was not usually concomitant at time of VZV reactivation. Common infections (respiratory, urinary tract, ear, and eye) in the SLE group exceeded controls, but not significantly (23% vs 9%; OR 2.98, p < 0.06) and SLE patients were more likely to have been vaccinated since 18 years of age with any type of vaccine (69% vs 51%; OR 2.21, p < 0.04). SLE patients were less likely than controls to report joint trauma within one year prior to their diagnosis (25% vs 40%; OR 0.49, p < 0.04). There were no differences with respect to streptococcal throat infection (p < 0.96), diarrhea/vomiting (p < 0.84), rash with fever (p < 0.07), parvovirus infection (p < 0.16), infection after surgery (p < 0.58), respiratory tract infection (p < 0.71), or ear (p < 0.09) and eye infection (p < 0.68) one year prior to diagnosis. A higher proportion of SLE patients had a history of urinary tract infections (46% vs 25%), but this was not significant (p < 0.17), nor was it significant one year prior to diagnosis (p < 0.63). Overall, the likelihood of having any infection one year prior to diagnosis was not significantly higher in the SLE group (p < 0.56). There were no differences one year prior to diagnosis in travel history (p < 0.69), hospitalizations (p < 0.47), use of antibiotics (p < 0.54), history of rheumatic fever, positive TB skin test, or hepatitis A, B or C infection.
Varicella reactivation as shingles is increased in patients with SLE and clusters around diagnosis. Vaccinations are increased in those with SLE compared to controls. Common infections are not significantly increased in SLE patients prior to onset of symptoms. We cannot determine if VZV infections are causally associated with SLE in some people, are from an abnormal immune system response due to the lupus itself or from the use of steroids or other immunosuppressive drugs to control the disease, or are spurious.
调查系统性红斑狼疮(SLE)诊断之前及诊断时感染的患病率,尤其是带状疱疹的发生率和水痘带状疱疹病毒(VZV)再激活的时间,以及抗生素使用、疫苗接种和关节创伤情况。
我们向SLE患者(n = 93)和患有非炎性肌肉骨骼疾病(MSK)的对照者(n = 353)发送了问卷,后者包括骨关节炎、纤维肌痛和肌腱炎。我们将SLE患者与对照者按性别进行匹配(最高1:3)。
SLE患者的应答率为66%,对照者为69%(p < 0.53)。61例SLE患者中有4例为男性,173例对照者中有12例为男性。SLE组的平均病程为8±1年,而对照组为10±1年(p < 0.23)。SLE患者明显比对照者年轻(SLE患者的平均年龄为49±2岁,对照者为57±1岁;p < 0.0004),结果已根据年龄进行调整。SLE参与者中VZV(带状疱疹)病史的比例明显更高(分别为19%和7%;OR 2.98,p < 0.003),而SLE中风疹的报告较少(23%对42%;OR 0.43,p < 0.03)。VZV感染在SLE诊断之前或之后聚集,但在对照者中时间间隔更宽(SLE诊断后1±4.5年,而非炎性MSK疾病诊断前-14.7±4年;p < 0.003)。在11例SLE患者中,6例在SLE诊断的±2年内诊断出带状疱疹,而15例对照者中只有2例在诊断的±2年内患有带状疱疹(OR 7.2,p < 0.03)。带状疱疹发作时,只有2例SLE患者正在服用免疫抑制药物或类固醇,因此VZV再激活时通常不伴有免疫抑制治疗。SLE组常见感染(呼吸道、泌尿道、耳部和眼部)超过对照者,但无显著差异(23%对9%;OR 2.98,p < 0.06),SLE患者自18岁起接种任何类型疫苗的可能性更高(69%对51%;OR 2.21,p < 0.04)。SLE患者在诊断前一年内报告关节创伤的可能性低于对照者(25%对40%;OR 0.49,p < 0.04)。在诊断前一年,链球菌性咽炎感染(p < 0.96)、腹泻/呕吐(p < 0.84)、发热伴皮疹(p < 0.07)、细小病毒感染(p < 0.16)、手术后感染(p < 0.58)、呼吸道感染(p < 0.71)或耳部(p < 0.09)和眼部感染(p < 0.68)方面无差异。SLE患者中有更高比例有尿路感染病史(46%对25%),但这无统计学意义(p < 0.17),在诊断前一年也无统计学意义(p < 0.63)。总体而言,SLE组在诊断前一年发生任何感染的可能性无显著更高(p < 0.56)。在诊断前一年,旅行史(p < 0.69)、住院情况(p < 0.47)、抗生素使用(p < 0.54)、风湿热病史、结核菌素皮肤试验阳性或甲型、乙型或丙型肝炎感染方面无差异。
SLE患者中带状疱疹形式的水痘再激活增加且在诊断前后聚集。与对照者相比,SLE患者的疫苗接种增加。SLE患者在症状出现前常见感染无显著增加。我们无法确定VZV感染在某些人中是否与SLE有因果关系,是源于狼疮本身引起的异常免疫系统反应还是使用类固醇或其他免疫抑制药物来控制疾病,亦或是虚假关联。